Dr. Punnonen is a Co-Founder of STATegics, Inc. and has served as the Company’s Chief Executive Officer since June 2007. He has 20 years of experience in growth factors and cytokines and an extensive track record in biotechnology with experience in building and managing R&D teams from discovery to development. Prior to founding STATegics, Inc., he served as Vice President, R&D and Head of Biology & Pharmacology at Maxygen, Inc. (MAXY), a company that develops next generation protein therapeutics and vaccines. He joined Maxygen at its founding in 1997, held both scientific and management positions, and served as Vice President from 2002 through 2007. Prior to Maxygen, Dr. Punnonen was a Scientist at DNAX Research Institute (Schering-Plough, SGP), a company involved in discovery and development of cytokine therapeutics. Earlier, he did his post-doctoral training at the Human Immunology Department of DNAX. Prior to DNAX, he worked as a clinician in internal medicine and as a family physician. Dr. Punnonen has 85 scientific publications, 20 patents or patent applications, and he received MD and PhD (immunology) degrees from the University of Turku, Finland, in 1989.
Jeffrey R. Spencer, PhD, Senior Vice President of Discovery Technologies.
Dr. Spencer brings 18 years of experience to STATegics in small molecule drug discovery and development. Prior to co-founding STATegics, Dr. Spencer was Senior Director and Head of Discovery Medicinal Chemistry at Celera Genomics in South San Francisco, CA, where he successfully advanced several small molecule discovery programs from screening to lead optimization. In 2001 when Applera Corporation acquired Axys Pharmaceuticals, Dr. Spencer was responsible for a team of researchers that focused on the structure-based design of novel leads for respiratory and oncology targets, ultimately leading to an IND filing for cancer. From 1995 to 2001, Dr. Spencer was the research leader of three major collaborations with Axys. Prior to that, from 1993 to 1995, Dr. Spencer was a postdoctoral fellow at the California Institute of Technology studying inhibitors of mammalian protein glycosylation, and in 1993 he graduated with a Ph.D. in organic chemistry from the University of California at San Diego.
Board of Directors
Juha Punnonen, MD, PhD, CEO, STATegics, Inc.
Jeffrey R. Spencer, PhD, Secretary, STATegics, Inc.